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Background: As one of the most frequent and serious adverse reactions 
during tuberculosis (TB) treatment, antituberculosis drug-induced liver 
injury (ATLI) in children has been studied insufficiently compared with 
adults. We aimed to determine the incidence and risk factors of ATLI in 
children during the first 2 months of TB therapy.
Methods: A total of 41 children with TB and treated with first-line anti-TB 
drugs were prospectively followed-up for the development of ATLI. Liver 
function tests were performed at baseline and after 2 weeks of therapy. Sub-
sequent tests were conducted at 4, 6 and 8 weeks if the initial 2-week meas-
urement was abnormal or if symptoms of hepatotoxicity were reported.
Results: ATLI was detected in 11 (27%) patients within 14 to 42 days from 
the start of therapy, with most of them (54%) occurred after 2 weeks. TB 
treatment was stopped immediately in 6 of 11 patients who developed ATLI, 
and no recurrent hepatotoxicity after drug reintroductions in these patients. 
Univariate analysis showed that ATLI was significantly associated with TB 
meningitis (P < 0.01), hypoalbuminemia (P < 0.05) and hepatotoxic come-
dications (P < 0.01). Age, sex, nutritional status, HIV status and baseline 
liver function abnormalities were not associated with ATLI. Multivariate 
analysis identified hypoalbuminemia and hepatotoxic comedications (both 
P < 0.1) tend to be independently associated with ATLI.
Conclusions: Children with hypoalbuminemia and use of hepatotoxic 
comedications are suggested to be monitored closely for the development 
of ATLI.
Key Words: tuberculosis, antituberculosis drugs, drug-induced liver injury, 
children, risk factors
(Pediatr Infect Dis J 2019;38:50–53)
Approximately 10.4 million people developed tuberculosis (TB) worldwide in 2016, of which 1 million (10%) are children. 
Furthermore, there are 1.3 million cases of TB deaths, with 82% 
of them occurring in low- and middle-income countries mostly in 
Africa and South-East Asia.1 Antituberculosis drug-induced liver 
injury (ATLI) is one of the most frequent and serious adverse reac-
tions during TB treatment.2 Isoniazid, rifampicin and pyrazina-
mide are the most potentially hepatotoxic first-line anti-TB drugs, 
whereas ethambutol and streptomycin have no known hepatotoxic-
ity reactions.3
ATLI has a significant role in diminishing treatment effec-
tiveness by increasing patient morbidity and mortality and disrupt-
ing therapy adherence.4,5 As an independent predictor of prolonged 
TB treatment,6 the high occurrence of ATLI results in discontinu-
ation of therapy and potentially treatment failure. In adults, vari-
ous factors, such as advanced age, female sex, malnutrition, HIV/
AIDS, preexistent liver disease (eg, hepatitis B/C infections), 
alcohol intoxication, hepatotoxic comedications and genetics, are 
reported to be associated with higher risk to develop ATLI.3
The incidence and factors associated with ATLI in children 
have been studied insufficiently compared with adults. Even though 
the incidence of ATLI is lower than in adults, ATLI can develop in 
children at any age or any dosage of anti-TB drugs, with signs and 
symptoms are frequently ignored in many cases.7 Similarly, data 
about ATLI in the Indonesian pediatric population are limited. An 
earlier study in Indonesia reported that the rate of ATLI in chil-
dren was about 7.4%.8 In the study, liver function tests (LFTs) were 
only performed in the first 2 weeks of therapy so that the actual 
incidence of ATLI was underestimated. Based on the 2014 World 
Health Organization guideline on the management of TB in chil-
dren, routine monitoring of liver functions is not mandatory during 
TB treatment. It is only recommended if liver tenderness, hepato-
megaly or jaundice occur during therapy.9 In addition, according to 
the national guidelines for childhood TB by the Indonesian Pediat-
ric Society (IDAI), LFTs are only performed if hepatic dysfunction 
is suspected before the treatment, or symptoms of hepatotoxicity 
(eg, jaundice) appear during therapy.10 In this context, this study 
aims to determine the incidence and risk factors associated with 
ATLI in Indonesian pediatric patients during the first 2 months (ie, 
the intensive phase) of TB treatment.
PATIENTS AND METHODS
We conducted a prospective observational study at the 
Department of Child Health of the M Djamil Hospital in Padang, 
Indonesia, from September 2015 to April 2016. All consecutive 
inpatients or outpatients from 1 to 15 years of age, diagnosed with 
active pulmonary TB or extra-pulmonary TB and treated with 
isoniazid, rifampicin and pyrazinamide with/without ethambutol 
were eligible for inclusion in this study. TB was clinically diag-
nosed using the pediatric TB scoring system developed by the IDAI 
(Table, Supplemental Digital Content 1A, http://links.lww.com/
INF/D280).10 Other procedures such as cerebrospinal fluid analy-
sis and head computed tomographic scan to confirm TB meningitis 
(TBM) were performed if applicable.
Patients were treated by pediatricians of the M Djamil Hos-
pital and were excluded if they had suspected multidrug resist-
ance TB or low adherence and failure to complete the treatment. 
Patients with suspected pre-existing liver diseases before starting 
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medication such as baseline aspartate aminotransferase (AST) or 
alanine aminotransferase (ALT) more than 3× the upper limit of 
normal (ULN), viral hepatitis B/C or clinical symptoms like hepa-
tomegaly and jaundice were also excluded.3 Suspected viral hepati-
tis B and/or C infections were defined by anamnesis of the clinical 
history, including perinatal transmission, blood transfusion history, 
sexual contact, infected household contact and direct percutaneous 
exposure to blood. All TB patients were screened and tested for 
HIV, and all HIV coinfected patients were initially treated with anti-
TB drugs only and had not started antiretroviral therapy until the 
completion of the intensive phase of therapy. Other comedications 
concomitantly used with anti-TB drugs were evaluated with the 
LiverTox Database for detailed information on drugs potentially 
causing drug-induced liver injury.11
Treatment Protocol
During the first 2 months of therapy, patients received a 
drug combination regimen based on the 2013 IDAI guideline in 
accordance with the 2014 World Health Organization guidance for 
the national TB programs on the management of TB, consisting of 
isoniazid, rifampicin and pyrazinamide for pulmonary TB and lym-
phadenitis TB; or isoniazid, rifampicin, pyrazinamide and etham-
butol for extensive pulmonary TB, TB meningitis and osteoarticu-
lar TB.9,10 The drug doses are described in the Table, Supplemental 
Digital Content 1B, http://links.lww.com/INF/D280.
Data Collection
Demographic data and clinical history were collected at pre-
treatment for each patient. Nutritional status was assessed by meas-
uring length/stature-for-age and weight-for-age percentiles based 
on the 2000 Centers for Disease Control and Prevention Growth 
Charts.12 LFTs, including ALT, AST and total bilirubin, were per-
formed at baseline and 2 weeks after initiation of therapy. Subse-
quent ALT, AST and total bilirubin were taken at 4, 6 and 8 weeks 
if the initial 2-week measurement was abnormal or if symptoms of 
hepatotoxicity such as anorexia, nausea, vomiting, abdominal pain 
or jaundice were reported.13 The reference normal values in our 
laboratory are ALT, <41 IU/L (male) and <31 IU/L (female); AST: 
<38 IU/L (male) and <32 IU/L (female); total bilirubin <1 mg/dL; 
serum albumin >3.7 g/dL.
Diagnosis and Management of ATLI
ATLI was defined as elevation of ALT/AST to more than 
3× the ULN. To stop TB treatment caused by ATLI, at least one of 
the following criteria must be fulfilled: (1) elevation of transami-
nase levels >3× the ULN with clinical symptoms of hepatotoxicity 
(nausea, vomiting, abdominal pain and jaundice) or >5× the ULN 
without the presence of symptoms; and (2) a rise in total bilirubin 
to more than 2 mg/dL in the presence of jaundice, both with nor-
malization of liver enzymes and resolving of symptoms of hepato-
toxicity after withdrawal of all anti-TB drugs.3,14,15 For those who 
stopped TB treatment, liver functions were measured weekly until 
the symptoms resolved, and transaminase levels declined to less 
than 2× the ULN. As suggested by the IDAI guideline, the original 
regimen was restarted simultaneously when the symptoms and liver 
enzymes normalized. Patients who have increased transaminases 
>3× the ULN without the presence of symptoms of hepatotoxicity 
still continued the treatment with closely followed-up.10
Statistical Analysis
Demographics and clinical factors considered for the study 
were age, sex, nutritional status, type of TB, albumin status, HIV 
status, concomitant hepatotoxic drugs and baseline LFTs, includ-
ing ALT, AST and total bilirubin. These variables were analyzed 
univariately using χ2/Fisher exact test to identify risk factors for 
ATLI. Multivariate binary logistic regression analysis was then 
used to identify independent risk factors for the development of 
ATLI. All variables with P value <0.2 in the univariate analy-
sis with numbers in both exposed and nonexposed groups >25% 
were included in multivariate analysis. Statistical significance was 
accepted at P < 0.05. All data were analyzed with IBM SPSS Sta-
tistics version 23.0.
Ethical Consideration
Ethical clearance was granted by the Research Ethics Com-
mittee, Faculty of Medicines, Andalas University (No: 076/KEP/
FK/2015). Written informed consent was obtained from parents/
guardians before the commencement of the study.
RESULTS
Forty-nine patients were screened and included in the study. 
Eight of these were excluded from analysis; 3 patients had with-
drawn from the study and 5 patients had incomplete clinical data 
due to technical problems during laboratory measurements (n = 2), 
and 3 patients diagnosed with TBM died within the first 2 weeks of 
treatment due to severity of the disease before the LFTs could be 
measured. Of the 41 patients available for analysis, there were 11 
and 14 patients with abnormal ALT and AST, respectively. Among 
them, there were 2 patients with baseline ALT >2× the ULN and 3 
patients with AST >2× the ULN. None of those who have baseline 
transaminases above 2× the ULN then developed into ATLI. Patient 
characteristics of the study population are presented in Table, Sup-
plemental Digital Content 2, http://links.lww.com/INF/D281.
During the first 2 months of therapy, ATLI was detected in 
11 (26.8%) patients within 14 to 42 days from the start of treatment. 
Six patients developed ATLI after 2 weeks of treatment, 3 patients 
developed ATLI after 4 weeks and 2 patients after 6 weeks. Of the 
11 patients who developed ATLI, 5 increased in both ALT and AST, 
3 increased in AST, 2 increased in ALT and 1 rose in bilirubin. 
All of the patients who developed ATLI were considered to have a 
stable condition including 9 inpatients with TBM and 2 outpatients 
with pulmonary TB.
There were 6 of 11 patients (5 with TBM and 1 with pul-
monary TB) in which all anti-TB drugs were stopped immediately. 
Among them, 3 patients with both ALT and AST >3× the ULN 
showed the symptoms of fever and nausea (2 patients); and nausea, 
vomiting as well as abdominal pain (1 patient). Two patients both 
experienced fever with ALT/AST >5× the ULN developed ATLI 
without other specific symptoms of hepatotoxicity. The remain-
ing 1 patient who rose in bilirubin >2 mg/dL experienced jaundice 
and anorexia. Both clinical symptoms and liver function profiles 
resolved within 1 week in 5 patients and within 2 weeks in the 
other one. After reintroducing anti-TB drugs, we performed LFTs 
fortnightly for all those 6 patients, and no ATLI recurrence was 
observed until the completion of the study.
The univariate analysis, shown in Table 1, demonstrated that 
TBM [P = 0.003; odds ratio (OR): 12.37; 95% confidence interval 
(CI): 2.18–69.99], hypoalbuminemia (P = 0.029; OR: 6.22; 95% 
CI: 1.33–29.01) and hepatotoxic comedications (P = 0.001; OR: 
20.00; 95% CI: 2.24–178.94) were significantly associated with 
ATLI. Sex, age, nutritional status, HIV status and abnormality of 
baseline LFTs (ALT, AST and total bilirubin) had no significant 
association with ATLI. Multivariate logistic regression analy-
sis identified hypoalbuminemia (P = 0.083; OR: 5.31; 95% CI: 
0.80–35.21) and concomitant hepatotoxic drugs (P = 0.078; OR: 
12.74; 95% CI: 0.75–216.12) tend to be independently associated 
with ATLI but not found statistically significant (Table 2). Potential 
hepatotoxic comedications used by patients who developed ATLI 
Copyright © 2018 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
Gafar et al The Pediatric Infectious Disease Journal • Volume 38, Number 1, January 2019
52 | www.pidj.com © 2018 Wolters Kluwer Health, Inc. All rights reserved.
were phenobarbital in 7 (63.6%), paracetamol in 5 (45.4%), ome-
prazole in 2 (18.2%), ranitidine in 2 (18.2%), phenytoin in 1 (9.1%) 
and captopril in 1 (9.1%) patients.
DISCUSSION
In our study, 27% of the patients were categorized as having 
ATLI and 15% stopped TB treatment caused by ATLI. This result 
was higher than reported in recent similar studies of children, such 
as in Indonesia (7.4%),8 in Japan (8.1%)16 and in India (15.2%).17 
This higher incidence could be related to transient and asympto-
matic elevations of transaminases, most of which represents hepatic 
adaptation with spontaneous resolution.14 As drug reintroduction 
regimens were well-tolerated in those who developed ATLI, it was 
likely that the initial hepatotoxic event could have been the result of 
hepatic adaptation. Because there is no golden standard to distin-
guish between true ATLI and hepatic adaptation, patients who had 
treatment interrupted in our study were more likely of concern for 
evolving ATLI rather than because of established hepatotoxicity. 
However, treatment discontinuation based on biochemical thresh-
olds and symptoms monitoring as suggested by standard guidelines 
would benefit to prevent severe progression of hepatic failure at an 
earlier stage.18
More patients in our study developed the clinical manifesta-
tion of nausea, and only few patients had jaundice, vomiting, ano-
rexia and abdominal pain, which were the most frequent symptoms 
occurring in other studies.19,20 Notably, 7 patients who developed 
ATLI in our study (including 2 patients who stopped TB treatment) 
were asymptomatic or had prodromal symptoms (eg, fever). Shang 
et al20 showed that a third of their patients who developed ATLI 
were asymptomatic, including patients with severe hepatotoxicity. 
In some cases, severe hepatotoxicity may have progressed into liver 
failure requiring liver transplantation.21,22 As severe hepatotoxic-
ity can occur without clinical symptoms, routine monitoring has 
proven to be effective in identifying asymptomatic liver damage 
reducing the need for hospitalization.23
The higher incidence of ATLI in children with TBM was 
supported by Donald7 who showed that abnormal LFTs and jaun-
dice were recorded, respectively, in 53% and in 10% of children 
during TB therapy. The reason why patients with TBM are more 
likely to have ATLI compared with other types of TB is still unclear 
but could be related to severity of the underlying disease.24 In 
addition, all patients with TBM in our study had used potentially 
hepatotoxic comedications, such as paracetamol and phenobarbi-
tal. Other studies also showed an association between hepatotoxic 
comedications with ATLI.25,26
The higher risk of hepatotoxicity in patients with hypoal-
buminemia may be related to depletion of glutathione stores, mak-
ing patients more vulnerable to oxidative injuries and disrupting 
hepatic drug metabolism.19 It seems that malnutrition as identified 
by hypoalbuminemia itself might be the sign of hepatic dysfunction, 
and the possibility that it was partly caused by liver damage cannot 
be ruled out. However, it is unlikely that this short term of hepato-
toxicity would have resulted in hypoalbuminemia as both clinical 
symptoms and liver function profiles resolved in all patients after 
stopping TB treatment, and no recurrent hepatotoxicity after drug 
reintroductions. Several previous studies also reported malnutrition 
including hypoalbuminemia and low Body Mass Index (BMI) to be 
associated with increased ATLI.19,25,27,28
Many studies reported that patients who are at higher risk of 
developing ATLI are associated with female sex, younger age (<5 
years), abnormal baseline LFTs and HIV positive.3,14 Nevertheless, 
we did not find similar results. Several possible mechanisms could 
be responsible for these differences, such as sample size, variations 
of pharmacokinetics and genetics.
Our study has several limitations that should be consid-
ered. Because all of the patients were diagnosed clinically instead 
of bacteriologically confirmed with TB, there was still a possibil-
ity of diagnosis interchange between latent TB infection and TB 
disease. This aspect could limit reproducibility and extrapolation 
of the results. Our diagnostic tool (IDAI TB scoring system) also 
needs to be confirmed in studies with diverse population before 
it can be generalized. We acknowledge that baseline elevation of 
transaminases above the ULN but below the exclusion threshold 
of 3× the ULN could be the sign of pre-existing hepatic dysfunc-
tions. However, there was no firm diagnosis that could explain these 
abnormalities in our study as we only excluded the possibility of 
viral hepatitis B or C coinfections by clinical anamnesis and were 
not able to test for viral hepatitis biomarkers. Because Indonesia 
is reported to have a moderate to high incidence of hepatitis B, 
and governmental pediatric vaccination against hepatitis B virus 
was only started since 1997, mothers of the included children were 
probably not immunized against it.29 If the mother was infected 
and transmitted the virus before the child got vaccinated, and no 
TABLE 1. Risk Factors Associated With ATLI Using Univariate Analysis
 ATLI Patients  (n = 11)
Non-ATLI Patients  
(n = 30) OR (95% CI) P Value
Female 5 (45.5) 10 (33.3) 1.67 (0.41–6.82) 0.491
Age 1–5 years 6 (54.5) 12 (40.0) 1.80 (0.45–7.25) 0.489
Underweight 9 (81.8) 16 (53.3) 3.94 (0.73–21.38) 0.152
TB meningitis 9 (81.8) 8 (26.7) 12.37 (2.18–69.99) 0.003*
Hypoalbuminemia 8 (72.7) 9 (30.0) 6.22 (1.33–29.01) 0.029*
Hepatotoxic comedications 10 (90.9) 10 (33.3) 20.0 (2.24–178.94) 0.001*
Abnormal baseline ALT 4 (36.4) 7 (23.3) 1.88 (0.42–8.34) 0.445
Abnormal baseline AST 5 (45.5) 9 (30.0) 1.94 (0.47–8.05) 0.463
Abnormal baseline total bilirubin 3 (27.3) 1 (3.3) 10.88 (0.99–119.24) 0.052
HIV positive 1 (9.1) 3 (10.0) 0.90 (0.08–9.69) 1.000
Data are presented as number (percentages).
TABLE 2. Independent Risk Factors Associated With 
ATLI Using Multivariate Analysis
 B
Adjusted OR  
(95% CI) P Value
Underweight 0.99 2.70 (0.34–21.69) 0.350
TB meningitis 0.74 2.09 (0.19–22.63) 0.554
Hypoalbuminemia 1.67 5.31 (0.80–35.21) 0.083
Hepatotoxic comedications 2.54 12.74 (0.75-216.12) 0.078
B indicates logistic regression coefficients.
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hepatitis B immunoglobulin was simultaneously administered 
within 24 hours of birth, the child would not be protected by vacci-
nation. This possibly resulted in misclassification of viral hepatitis 
to ATLI in some patients.
Apart from the relatively small sample size of patients which 
limits the power of the study, we monitored the liver functions only 
for the first 2 months of TB treatment. Although hepatotoxicity 
most often occurs in the first 2 months, the actual eventual hepato-
toxicity rate by the end of therapy could be higher. Our method was 
also unable to clearly clarify asymptomatic hepatotoxicity after 2 
weeks as LFTs at 4, 6 and 8 weeks were only performed for patients 
with symptomatic disease. Then, we acknowledge that AST is not 
as specific as ALT to determine hepatotoxicity related to anti-TB 
drugs although both ALT and AST have been used as biomark-
ers of ATLI in various studies.3 The increase of AST alone cannot 
clearly define hepatocellular injury and may lead to the inclusion 
of patients without ATLI. Therefore, our exclusion criteria, specific 
monitoring of LFTs and a low threshold for defining hepatotoxicity 
potentially resulted in an underestimation of ATLI. Further studies 
with larger sample sizes over a longer time frame would provide a 
clearer picture of ATLI in children.
In conclusion, the incidence rate of ATLI in children treated 
with anti-TB drugs is quite high. Patients with hypoalbuminemia 
and those who use concomitant hepatotoxic drugs are suggested to 
be monitored closely for the development of ATLI. These findings 
can aid clinicians to be aware of the problem particularly in patients 
with hypoalbuminemia and benefit for patients who could avoid 
hepatotoxic comedications during TB therapy.
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